Do you want to link to this External Website and leave Amgen.sa?

YOU ARE NOW LEAVING THIS WEBSITE.

Amgen Saudi Arabia takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

Investors Relation Arabic Amgen Worldwide Web Resources Search

Amgen Worldwide

A biotechnology pioneer since 1980, Amgen has reached millions of patients around the world.

Resources

Amgen has created a number of websites to better serve you with specific questions.

Scientific sources

Amgen discovers, develops, produces and supplies innovative medicines for patients suffering from serious illnesses. We support health care professionals and patients in the administration and optimization of our innovative therapies.

Below you can see the medicines available in the Saudi Arabia:

Oncology
Hematology (blood)
Kidney disease
Cardiovascular disease
Osteoporosis
Inflammatory Diseases

Oncology

Aransep
Aranesp is a medicine to treat anemia. Anemia is when your blood does not contain enough red blood cells and the symptoms may be fatigue, weakness and shortness of breath. Aranesp is used to treat symptomatic anemia that is associated with chronic renal failure (kidney failure) in adults and children. Aranesp is also used to treat symptomatic anemia in adult cancer patients with non-myeloid malignancies who are receiving chemotherapy.

xgeva
XGEVA is used in adults with advanced cancer to prevent serious complications caused by bone metastasis (e.g. fracture, pressure on the spinal cord or the need to receive radiation therapy or surgery).

Vectibix
Vectibix is used in the treatment of metastatic colorectal cancer (cancer of the bowel) for adult patients with a certain type of tumor known as a “Wild-type RAS tumor”.

LUMAKRAS
LUMAKRAS is indicated for the treatment of adult patients with KRAS G12C mutated locally advanced or metastatic non small cell lung cancer (NSCLC), who have received at least one prior systemic therapy.

 

Source: Patient information leaflets, Amgen. See www.ema.europa.eu for the most up-to-date versions.

Hematology (blood)

Blincyto
BLINCYTO is used to treat adults with acute lymphoblastic leukaemia. BLINCYTO is used when acute lymphoblastic leukaemia has come back or has not responded to previous treatment (referred to as relapsed/refractory acute lymphoblastic leukaemia).

BLINCYTO is used to treat children (≥ 1 year old), teenagers and young adults with acute lymphoblastic leukaemia when previous treatments have not worked or have stopped working.

It is also used in patients with acute lymphoblastic leukaemia who still have a small number of cancer cells remaining after previous treatment (referred to as minimal residual disease).

Acute lymphoblastic leukaemia is a cancer of the blood in which a particular kind of white blood cell called “B-lymphocyte” is growing out of control.

Kyprolis
Kyprolis is used to treat adult patients with multiple myeloma who have had at least one previous treatment for this disease. Multiple myeloma is a cancer of plasma cells (a type of white blood cell).

Nplate
Nplate is used to treat low platelet (thrombocyte) counts in patients with Immune Mediated Trombocytopenia (also known as ITP).

ITP is a disease in which your body’s immune system destroys its own platelets.

 

Source: Patient information leaflets, Amgen. See www.ema.europa.eu for the most up-to-date versions.

Kidney Disease

Aransep
Aranesp is a medicine to treat anemia. Anemia is when your blood does not contain enough red blood cells and the symptoms may be fatigue, weakness and shortness of breath. Aranesp is used to treat symptomatic anemia that is associated with chronic renal failure (kidney failure) in adults and children. Aranesp is also used to treat symptomatic anemia in adult cancer patients with non-myeloid malignancies who are receiving chemotherapy.

Mimpara
    Mimpara is used (in adults):
  • to treat secondary hyperparathyroidism in adults with serious kidney disease who need dialysis to clear their blood of waste products.
  • to reduce high levels of calcium in the blood (hypercalcemia) in adult patients with parathyroid cancer.
  • to reduce high levels of calcium in the blood (hypercalcemia) in adult patients with primary hyperparathyroidism when removal of the gland is not possible.

Mimpara is used in children aged 3 years to less than 18 years of age: to treat secondary hyperparathyroidism in patients with serious kidney disease who need dialysis to clear their blood of waste products, whose condition is not controlled with other treatments.

Parsabiv
Parsabiv is used to treat secondary hyperparathyroidism in patients with serious kidney disease who need hemodialysis to clear their blood of waste products.

 

Source: Patient information leaflets, Amgen. See www.ema.europa.eu for the most up-to-date versions.

Cardiovascular disease

Repatha

Repatha is a medicine that lowers levels of ’bad’ cholesterol, a type of fat, in the blood.

 

Source: Patient information leaflets, Amgen. See www.ema.europa.eu for the most up-to-date versions.

OSTEOPOROSIS

Prolia
Prolia is used to treat
  • osteoporosis in women after the menopause (postmenopausal) and men who have an increased risk of fracture (broken bones), reducing the risk of spinal, non-spinal and hip fractures.
  • bone loss that results from a reduction in hormone (testosterone) level caused by surgery or treatment with medicines in patients with prostate cancer.
  • bone loss that results from long-term treatment with glucocorticoids in patients who have an increased risk of fracture.

Treatment with Prolia makes bone stronger and less likely to break.

Evenity
EVENITY is a sclerostin inhibitor indicated for the treatment of osteoporosis in postmenopausal women at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy

 

Source: Patient information leaflets, Amgen. See www.ema.europa.eu for the most up-to-date versions.

Inflammatory Diseases

Amgevita
A physician may prescribe AMGEVITA for the treatment of various inflammatory diseases. AMGEVITA contains the active ingredient adalimumab. Amgevita is used for the treatment of:
  • Rheumatoid Arthritis
  • Juvenile Idiopathic Arthritis
  • Axial Spondyloarthritis
  • Psoriatic arthritis
  • Psoriasis
  • Pediatric Plaque Psoriasis
  • Hidradenitis suppurativa
  • Pediatric Plaque Psoriasis
  • Crohn’s Disease
  • Ulcerative colitis
  • Uveitis

Otezla
Otezla contains the active substance ‘apremilast’. This belongs to a group of medicines called phosphodiesterase 4 inhibitors, which help to reduce inflammation.

 

Source: Patient information leaflets, Amgen. See www.ema.europa.eu for the most up-to-date versions.

Products

Our medicines

Amgen Biosimilars

Medical Information